Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

189 - Imaging-proven Venous Thromboembolism Breast Cancer in a Tertiary Hospital in the Philippines


24 Nov 2018


Poster display - Cocktail


Staging and Imaging;  Cancer Care Equity Principles and Health Economics;  Supportive and Palliative Care

Tumour Site

Breast Cancer


Amabelle Trina Gerona


Annals of Oncology (2018) 29 (suppl_9): ix8-ix12. 10.1093/annonc/mdy427


A.T.B. Gerona

Author affiliations

  • Medical Oncology, ST. Luke's Medical Center, 11104 - Quezon City/PH


Abstract 189


Venous thromboembolism (VTE) is a common cause of mortality in cancer patients. This study looks into the most common malignancy in our institution, breast cancer, and its association with VTE.


Anonymised hospital patient database for years 2010-2015 with either Venous Dupplex Scan or Computed Tomographic Pulmonary Angiography. Each result was reviewed bearing acute pulmonary embolism or acute venous thrombosis. Only the first VTE event after the diagnosis of cancer was considered followed by chart review.


A total of 10,380 CTPA/Venous duplex scans were performed, with 916 (8.8%) positive VTE. Malignancy was seen in 208 (2%) with the majority 17.9% (n = 37) having breast cancer. Mean age for breast cancer with VTE was 60, majority 24 (64.8%) having normal BMI. Most had lower extremity VTE 28 (75.67%) presented as swelling of extremities 18 (48.6%). VTE within one year of cancer diagnosis was noted in 57.7% while 43.2% were alive for >2 years from VTE diagnosis. Active cancer management during diagnosis were chemotherapy 45.9%, hormonal therapy 32.4%, surgery 10.8%, while 10.8% had VTE as the presenting symptom of cancer diagnosis. VTE during chemotherapy days was seen in 64.7% while 35% had VTE one month after completion of chemotherapy. Those with hormonal therapy 10 (83.3%) had aromatase inhibitor, while only 2 (5.4%) received tamoxifen.


Breast cancer with VTE in our institution have normal BMI, presenting mostly as swelling of lower extremity. VTE was seen mostly within one year of cancer diagnosis and patients were alive for more than two years from VTE diagnosis. Active cancer management during VTE diagnosis was mostly during chemotherapy, followed by hormonal treatment with aromatase inhibitor.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Dr. Agnes E. Gorospe.


Has not received any funding.


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.